Novan Company Profile (NASDAQ:NOVN)

About Novan (NASDAQ:NOVN)

Novan logoNovan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company's formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $78.57 million
  • Outstanding Shares: 15,969,000
Average Prices:
  • 50 Day Moving Avg: $5.27
  • 200 Day Moving Avg: $13.05
  • 52 Week Range: $3.52 - $30.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.57
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $100,000.00
  • Price / Sales: 785.67
  • Book Value: $1.30 per share
  • Price / Book: 3.78
  • EBIDTA: ($58,360,000.00)
  • Current Ratio: 2.92%
  • Quick Ratio: 2.92%
  • Average Volume: 259,010 shs.
  • Short Ratio: 1.44

Frequently Asked Questions for Novan (NASDAQ:NOVN)

What is Novan's stock symbol?

Novan trades on the NASDAQ under the ticker symbol "NOVN."

How were Novan's earnings last quarter?

Novan Inc (NASDAQ:NOVN) announced its quarterly earnings data on Friday, May, 12th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.24. The company earned $0.10 million during the quarter, compared to analyst estimates of $10.80 million. View Novan's Earnings History.

Where is Novan's stock going? Where will Novan's stock price be in 2017?

4 brokers have issued 1 year target prices for Novan's stock. Their predictions range from $8.00 to $31.00. On average, they anticipate Novan's share price to reach $17.24 in the next twelve months. View Analyst Ratings for Novan.

Are investors shorting Novan?

Novan saw a increase in short interest in April. As of April 28th, there was short interest totalling 1,157,866 shares, an increase of 31.3% from the April 13th total of 881,898 shares. Based on an average trading volume of 165,909 shares, the days-to-cover ratio is presently 7.0 days. Approximately 12.8% of the company's stock are short sold.

Who are some of Novan's key competitors?

When did Novan IPO?

(NOVN) raised $46 million in an IPO on Wednesday, September 21st 2016. The company issued 3,800,000 shares at a price of $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who owns Novan stock?

Novan's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Driehaus Capital Management LLC (1.75%), Vanguard Group Inc. (1.14%), Geode Capital Management LLC (0.38%) and Prospera Financial Services Inc (0.17%). View Institutional Ownership Trends for Novan.

Who bought Novan stock? Who is buying Novan stock?

Novan's stock was acquired by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Vanguard Group Inc., Prospera Financial Services Inc and Geode Capital Management LLC. View Insider Buying and Selling for Novan.

How do I buy Novan stock?

Shares of Novan can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Novan stock cost?

One share of Novan stock can currently be purchased for approximately $4.92.

Analyst Ratings

Consensus Ratings for Novan (NASDAQ:NOVN) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $17.24 (250.46% upside)

Analysts' Ratings History for Novan (NASDAQ:NOVN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/12/2017Piper Jaffray CompaniesSet Price TargetBuy$11.00LowView Rating Details
4/12/2017WedbushReiterated RatingNeutral$8.00HighView Rating Details
10/17/2016Credit Suisse Group AGInitiated CoverageOutperform$27.00 -> $18.97N/AView Rating Details
10/17/2016JMP SecuritiesInitiated CoverageOutperform$31.00N/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for Novan (NASDAQ:NOVN)
Earnings by Quarter for Novan (NASDAQ:NOVN)
Earnings History by Quarter for Novan (NASDAQ:NOVN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/12/2017Q1 2017($0.49)($0.73)$10.80 million$0.10 millionViewN/AView Earnings Details
3/20/2017Q4 16($1.14)($0.82)ViewN/AView Earnings Details
11/14/2016Q3 16($1.40)($5.76)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Novan (NASDAQ:NOVN)
2017 EPS Consensus Estimate: ($1.28)
2018 EPS Consensus Estimate: ($1.26)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.19)($0.19)($0.19)
Q2 20171($0.57)($0.57)($0.57)
Q3 20171($0.27)($0.27)($0.27)
Q4 20171($0.25)($0.25)($0.25)
Q1 20181($0.21)($0.21)($0.21)
Q2 20181($0.27)($0.27)($0.27)
Q3 20181($0.35)($0.35)($0.35)
Q4 20181($0.43)($0.43)($0.43)
(Data provided by Zacks Investment Research)


Dividend History for Novan (NASDAQ:NOVN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Novan (NASDAQ:NOVN)
Institutional Ownership Percentage: 12.75%
Insider Trades by Quarter for Novan (NASDAQ:NOVN)
Institutional Ownership by Quarter for Novan (NASDAQ:NOVN)
Insider Trades by Quarter for Novan (NASDAQ:NOVN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/26/2016Life Sciences Holdings L MalinMajor ShareholderBuy800,000$11.00$8,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Novan (NASDAQ:NOVN)
Latest Headlines for Novan (NASDAQ:NOVN)
DateHeadline logoNovan Inc Expected to Post Q2 2017 Earnings of ($0.57) Per Share (NOVN) - May 17 at 7:46 AM logoZacks: Brokerages Anticipate Novan Inc (NOVN) to Announce -$0.58 Earnings Per Share - May 16 at 2:18 PM logoNovan Inc (NOVN) Posts Earnings Results, Misses Estimates By $0.24 EPS - May 15 at 11:18 AM logoNovan Inc (NOVN) Sees Significant Increase in Short Interest - May 13 at 7:20 AM logoZacks: Analysts Set $9.50 Target Price for Novan Inc (NOVN) - May 6 at 12:34 AM logoNovartis exercises exclusive option agreement with Conatus for the treatment of NASH - May 4 at 11:19 AM logoNovan Presents Preclinical Data from Inflammatory Skin Diseases Program - April 27 at 10:05 AM logoNovan Presents Safety Data for SB204 Program - April 27 at 10:05 AM logoAlcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma - April 26 at 6:24 PM logo Novan Inc (NOVN) Receives Consensus Rating of "Buy" from Analysts - April 20 at 8:28 PM logoNovartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL - April 18 at 10:06 AM logoNovan Inc (NOVN) Given a $11.00 Price Target by Piper Jaffray Companies Analysts - April 18 at 7:47 AM logoPre-Open Stock Movers 04/12: (NOVN) (NBIX) (BBRY) Higher; (NS) (ONVO) (TSCO) Lower (more...) - April 13 at 8:14 AM logoNovan Inc (NOVN) Receives "Neutral" Rating from Wedbush - April 12 at 2:01 PM logo11 Biggest Mid-Day Gainers For Wednesday - April 12 at 1:36 PM logo19 Stocks Moving In Wednesday's Pre-Market Session - April 12 at 10:25 AM logoNovan Inc. (NOVN) Is Up Sharply On Phase 2 Study Results - April 12 at 10:25 AM logoNovan Reports Positive Topline Results with SB208 in Phase 2 Trial - April 12 at 10:25 AM logoNovan's stock rockets after positive trial results - April 12 at 10:25 AM logoExclusive: Novan CEO Talks Strategic Partnerships, 2017 Pipeline, Finance Evaluation - March 27 at 6:21 PM logoAnalysts Issue Forecasts for Novan Inc's Q1 2017 Earnings (NOVN) - March 23 at 10:16 AM logoNovan (NOVN) Reports Departure of CFO Richard Peterson - March 22 at 6:54 PM logoNovan Reshapes Executive Management Team - March 22 at 6:54 PM logoNovan Inc (NOVN) Announces Quarterly Earnings Results - March 21 at 8:31 AM logoNovan’s loss grew in 2016, but optimistic on development - March 20 at 4:59 PM logoWedbush Reiterates Neutral Rating for Novan Inc (NOVN) - March 20 at 4:24 PM logoNovan Reports Fourth Quarter and Full Year 2016 Financial Results - March 20 at 9:57 AM logoNOVAN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 20 at 9:57 AM logoSandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk) - March 13 at 10:05 AM logoNovan Provides Update on SB204 Development Program - March 6 at 6:21 PM logoNovan stocks trading up after plummeting earlier this year - March 6 at 6:21 PM logoHere's Why Novan Inc. Is Rising Today - March 6 at 1:05 PM logoNovan Announces SB204 Program Update Conference Call and Webcast - March 3 at 11:53 PM logoNovan (NOVN) SB206 Phase 2 Results to be Presented at AAD - - March 3 at 6:51 PM logoNovan Announces SB204 Program Update Conference Call and Webcast - GlobeNewswire (press release) - March 3 at 6:51 PM logoNovan Announces Presentation of Anti-Viral Data at International Papillomavirus Conference - March 1 at 10:37 AM logoRGLS Disappointed, NOVN Loses Face Over Acne Trial Data, AMGN Abuzz - January 29 at 7:23 PM logoNovan Reports Topline Results from SB204 Phase 3 Pivotal Trials - January 29 at 12:00 AM logoNovan (NOVN) Names Anne Whitaker as CEO - January 26 at 11:25 PM logoAlcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgery - January 26 at 2:14 AM logoNovartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report - January 26 at 2:14 AM logoNovan (NOVN) Enters Licenses Agrement for SB204 with Sato Pharmaceutical in Japan - January 19 at 12:29 AM logoNovan Licenses SB204 to Sato for Acne in Japan - January 17 at 11:28 AM logoNOVAN, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - January 17 at 11:28 AM logo9:14 am Novan enters into an exclusive license agreement with Sato Pharmaceutical; will receive approx. $11 mln for the exclusive rights to develop and commercialize in Japan its SB204 for the treatment of acne vulgaris - January 17 at 11:28 AM logoNovartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders - January 6 at 2:33 AM logoNovartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases - December 20 at 12:49 PM logoNovartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc. - December 20 at 12:49 PM logoNovartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines - December 12 at 10:03 AM logoNovan CEO Talks About The Company's Future: 'Our Focus Is Put On SB204' - December 9 at 11:52 PM



Novan (NOVN) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff